Recommendations on the Treatment of Tobacco Dependence;Recomendaciones para el Tratamiento del Tabaquismo

Archivos de Bronconeumologia

Volumn 39, Issue 11, 2003, Pages 514-523

  Jimenez Ruiz C A ^a   De Granda Orive, J I ^b   Solano Reina, S ^b   Carrion Valero F ^b   Romero Palacios, P ^b   Barrueco Ferrero, M ^b  

^a Grupo de Intervencion en Drogas de la Sociedad Espanola de Medicina Familiar Y Comunitaria   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ABSORPTION; HUMAN; MENTAL DISEASE; REVIEW; SMOKING CESSATION; TOBACCO DEPENDENCE;

EID: 0242578544     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13053216     Document Type: Review

References (86)

1. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. Treating tobacco use and dependence. Clinical Practice guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service, June 2000.
2. Fiore MC, Joremby, DE, Schensky AE, Smith SS, Bauer RR. Baker TB. Smoking status as the new vital sign: effect on assessment and intervention in the patients who smoke. Mayo Clin Proc 1995;70:209-13.
3. Banegas Banegas JR, Díez Gañan L, Rodríguez-Artalejo F, González Enríquez J, Graciani A, Villar F. Mortalidad atribuible al tabaquismo en España en 1998. Med Clin (Barc) 2001;117:692-4.
4. World Health Organization. The European report on tobacco control policy. WHO European ministerial conference for a tobacco-free Europe. Warsaw: World Health Organization, Feb 18-19, 2002.
5. Peto R. Smoking and death: the past 40 years and the next 40. BMJ 1994;309:937-9.
6. Jiménez Ruiz CA, Solano Reina S, González de Vega JM, Ruiz Pardo M, Flórez Martín S, Ramos Pinedo A, et al. Normativa para el tratamiento del tabaquismo. Arch Bronconeumol 1999;335:499-506.
7. Jiménez Ruiz CA, Solano Reina S, Barrueco Ferrero M, de Granda Orive JI, Lorza Blasco JJ, Alonso Viteri S, et al. Recomendaciones para la organización y funcionamiento de las unidades especializadas en tabaquismo. Arch Bronconeumol 2001;37:382-7.
8. Jiménez Ruiz CA, Barrueco Ferrero M, Solano Reina S, Torrecilla García M, Domínguez Grandal F, Díaz-Maroto Muñoz JL, et al. Recomendaciones en el abordaje diagnóstico y terapéutico del tabaquismo. Documento de consenso. Arch Bronconeumol 2003;39: 35-41.
9. Jiménez Ruiz CA, Ayesta J, Planchuelo MA, Abéngozar R, Torrecilla M, Quintas AM, et al. Recomendaciones de la Sociedad Española de Especialistas en Tabaquismo para el tratamiento farmacológico del tabaquismo. Prev Tab 2001;3:78-85.
10. Ayudar a dejar de fumar. Protocolos de actuación para profesionales de salud. Programa de ayuda al fumador. Instituto de Salud Pública. Gobierno de Navarra. Departamento de Salud. Pamplona: Fondo de publicaciones del Gobierno de Navarra, 1990.
11. The smoking cessation clinical practice guideline. Panel and staff. The Agency for Health Care Policy and Research. JAMA 1996; 275:1270-80.
12. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000;55:987-99.
13. Akehurst RL, Bernett D, Berry C, Bird S, Buxton M, Claxton K, et al. Guidance on the use of nicotine replacement therapy and bupropion for smoking cessation. National Institute for Clinical Excellence. Disponible en: www.nice.org.uk
14. World Health Organization. European Partnership project. First European guideline in the treatment of tobacco dependence. Genève: October 1999.
15. Andersson JE, Joremby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence. Chest 2002;121:932-41.
16. Silagy C, Stead LF. Physician advice for smoking cessation. Cochrane Library. N 2. Oxford: Update software, 2000.
17. Silagy C. Physician advice for smoking cessation. Cochrane Library. N 2. Oxford: Update software, 2001.
18. Rice VH, Stead LF. Nursing interventions for smoking cessation. Cochrane Library. N 3. Oxford: Update software, 2001.
19. Rice VH, Stead LF. Nursing interventions for smoking cessation. Cochrane Library. N 2. Oxford: Update software, 2000.
20. Hajek P, Taylor TZ, Mills P. Brief intervention during hospital admission to help patients to give up smoking after myocardial infarction and bypass surgery: randomised controlled trial. BMJ 2002;324:87-9.
21. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Library. N 2. Oxford: Update software, 2000.
22. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Library. N 2. Oxford: Update software, 2001.
23. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Library. N 1. Oxford: Update software, 2002.
24. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane library. N 1. Oxford: Update software, 2002.
25. Stead LF, Lancaster T. Telephone counselling for smoking cessation. Cochrane library. N 2. Oxford: Update software, 2001.
26. Sutherland G. Current approaches to the management of smoking cessation. Drug 2002;62(Suppl 2):53-61.
27. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Library. N 2. Oxford:. Update software. 2000.
28. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Library. N 1. Oxford: Update software. 2002.
29. Park E, Schultz JK, Tudiver F, Campbell T, Becker L. Enhancing partner support to improve smoking cessation. Cochrane Library. N 1. Oxford: Update software, 2002.
30. Ussher Mh, West R, Taylor AH, McEwen A. Exercise interventions for smoking cessation. Cochrane Library. N 3. Oxford: Update software, 2000.
31. Jiménez Ruiz CA. Terapia sustitutiva con nicotina: aspectos prácticos. Rev Clin Esp 1998;198(3):181-5.
32. Paoletti P, Formai E, Maggiorelli F, Puntoni R, Viegi G, Carruzzi L, et al. Importance of baseline cotinine plasma values in smoking cessation: results from a double blind study with nicotine patch. Eur Resp J 1996;9:643-51.
33. Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Library. N 2. Oxford: Update software, 2000.
34. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Library. N 3. Oxford: Update software. 2001.
35. Thorndike AN, Biener L, Rigotti NA. Effect on smoking cessation of switching nicotine replacement therapy to over the counter status. Am J Public Health 2002;92(3):437-42.
36. McNeill A, Foulds J, Bates C. Regulation of nicotine replacement therapy: a critique of current practice. Addiction 2001;96(12): 1757-68.
37. Jiménez Ruiz CA, Ramos Pinedo A, Flórez Martín S, Steen B, Ramos Casado L. Terapia sustitutiva con nicotina. En: Barrueco M, editor. Manual de prevención y tratamiento del tabaquismo. Salamanca: Editorial Panan, 2001; p. 93-109.
38. Consejo general de colegios oficiales de farmacéuticos. Base de datos de medicamentos. Disponible en URL: www.Portalfarm.com/home.nsf
39. Tonnessen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE-trial. Eur Respir 1999;13:238-46.
40. Schneider M. Nicotine therapy in smoking cessation. Pharmacokinetic considerations. Clin Pharmacokinetic 1992;23:169-72.
41. Blondal T, Frazon M, Westein A. A double blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Resp J 1997;10:1585-90.
42. Jiménez Ruiz CA. Terapia sustitutiva con nicotina. En: Meana JJ, Markez I, Pantoja L, editores. Nicotina y tabaquismo. Nuevas perspectivas. Bilbao: Instituto Deusto de Drogodependencias. Universidad de Deusto, 1999; p. 151-83.
43. Dautzenberg M. Multicentre controlled study with nicotine pills. Paris: 3rd SRNT European Conference, 2001.
44. Balfour DJK. The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion. Int J Clin Pract 2001; 56:79-83.
45. Jarvis M, Powell S, Marsh H. A meta-analysis of clinical studies confirms the effectiveness of bupropion SR in smoking cessation. 7th Annual Conference of the Society for Research of Nicotine and Tobacco. Seattle. Washington, 2001.
46. Johnston JA, Fiedler-Kelly J, Glover ED, Pickman DE. Relationship between drug exposure and the efficacy and safety of bupropion SR for smoking cessation. Nicotine Tob Res 2001;23:744-52.
47. Zyban. Sustained relased tablets: product information. UK: GlaxoSmithKline, 2001.
48. Tashkin DP, Kanner R, Bailey W, Buist S, Anderson P, Nides MA, et al. Smoking cessation in patients with COPD: a double-blind, placebo-controlled, randomised study. Lancet 2001;357:1571-5.
49. Tonstad S. Use of bupropion SR in specific patient populations for smoking cessation. Drug 2002;62(Suppl 2):37-43.
50. Aubin H. Tolerability and safety of bupropion SR in the management of smoking cessation. Drug 2002;62(Suppl 2):45-52.
51. Joseph A, Norman S, Ferry L, Prochezke A, Westman E, Steel B, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8.
52. Working group for the study of transdermal nicotine in patients with coronary artery disease. Nicotine replacement therapy for patients with coronary disease. Arch Intern Med 1994;154:985-95.
53. Huhtasaari F, Asplund K, Lundberg V, Stegmair B, Wester PO. Tobacco and myocardial infarction. Is snuff less dangerous than cigarettes? BMJ 1992;305:1252-6.
54. Covey LS, Glassman AH, Statner F, Jonhston A. Effects of history of alcoholism or major depression on smoking cessation. Am J Psychiatry 1993;150:1546-7.
55. Hurt RD, Dale LC, Offord KP. Nicotine patch therapy for smoking cessation in recovering alcoholics. Addiction 1995;90:1541-6.
56. Hayford KD, Patten CA, Rummans TA, Covey LS. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999;174:173-8.
57. Glassman AH, Steiner F, Walsh BT, Covey LS. Heavy smokers, smoking cessation and clonidine: results of a double-blind randomised trial. JAMA 1988;259:2863-6.
58. Smith SS, Joremby DE, Leischow SJ, Dale LC. Targeting smokers at high risk for relapse: treating women and those with a history of depression. Chicago: 8th Annual Conference of the Society for Research on Nicotine and Tobacco, 2000.
59. Bjornson W, Rand C, Connet JE, Bailey B. Gender differences in smoking cessation after 3 years in the Lung Health Study. Am J Public Health 1995;85:223-30.
60. Swan GE, Jack LM, Ward GM, Wetter DW. Subgroup of smokers with different success rate after use of transdermal nicotine. Addiction 1997;92:207-17.
61. Joremby DE, Leischow SJ, Nides MA, Johnston A, Glover A. A controlled trial of bupropion SR, a nicotine patch or both for smoking cessation. N Engl J Med 1999;340:685-91.
62. Meyers AW, Klesges RC, Winders SE, Routh GR. Are weight predictive of smoking cessation?: a prospective analysis. J Consult Clin Psychol 1997;65:448-52.
63. Rigotti NA, Torndike AN, Niaura R, Scharf GF, Wetter DW. Post-cessation weight gain in smokers taking bupropion: the effect of gender. Arlington: 6th Annual Conference of the Society for Research of Nicotine and Tobacco, 2000.
64. Tonnesen P, Norregaard J, Sawe U, Gustavsson G, Kruise E. Recycling with nicotine patches in smoking cessation. Addiction 1993;88:533-9.
65. Hughes JR, Grass JA, Pilitteri JL. Treatment resistant smokers. A pilot study of nicotine nasal spray and inhaler. J Addict Dis 2000; 19:95-100.
66. Gonzales DH, Nides MA, Ferry LH, Jonhston A, Durcan J. Retreating relapse: bupropion SR v. placebo in adult cigarettes smokers previously treated with bupropion SR. Paris: 3rd Annual European Conference of the Society for Research of Nicotine and Tobacco, 2001.
67. Hatsukami D, Rennard S, Malcolm R, Gonzales DH, Nides MA. A multi-center study examining the effects of bupropion SR vs placebo as an aid to smoking reduction leading to cessation among smokers unwilling and unable to quit. Paris: 3rd Annual European Conference of the Society for Research of Nicotine and Tobacco, 2001.
68. Heatherton TF, Kozlowsky LT, Frecker RC, Baker T, Whisler W, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 1991;86:1119-27.
69. Payne TJ, Smith PD, McCracken LE, McSherry W, Antony MM. Assessing nicotine dependence: a comparison of the FTQ with the FTND in a clinical sample. Addict Behav 1994;19:307-17.
70. Shiffman S, Pilliteri JL, Burton SL, Rohay JM, Gitchell JE. Smokers beliefs about light and ultra light cigarettes. Tob Control 2001;10(Suppl 1):17-23.
71. Hughes J, Higgins S, Hatsukami. Effects of abstinence from tobacco, a critical review. En: Kozlowiski, et al, editors. Research advances in alcohol and drug problems. New York: Plenum Press 1990; p. 317-98.
72. Durcan MJ, Deener G, White J, Jonhston A, Gonzales D, Niaura R, et al. The effect of bupropion SR on cigarette craving after smoking cessation. Clin Ther 2002;24:540-51.
73. Lindblan A, Marsal K, Andersson K. Effect of nicotine in human fetal flow. Obstet Gynecol 1988;72:371-82.
74. Onkem C. Nicotine replacement during pregnancy. Am J Health Behav 1996;20:300-3.
75. Wisborg K, Brink T, Birk L, Jorgen N. Nicotine patches for pregnant smokers: a randomised controlled study. Obstet Gynecol 2000;96:967-71.
76. Wisborg K, Henriksen TB. Hedegaard M, Secher NG. Smoking cessation among pregnant women. Ugeskr Laeger 1996;158:3784-8.
77. Murray PR, Bailey W, Daniels K, Bjoruson WM, Kurnov R, Connett J, et al. Safety of nicotine policrilex gum used by 3094 participants in the lung health study. Chest 1996;109:438-45.
78. Joseph A, Norman S, Ferry L, Prochezke A, Westman E, Steel B. et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N. Engl J Med 1996;335: 1792-8.
79. Tonstad S, Murphy M, Ashbury C, Swan TH, Pietti HT, Covey LS, et al. Effectiveness and tolerability of bupropion SR in smokers cardiovascular disease. Week 26 follow up phase results. Stockholm: European Society of Cardiology, 2001.
80. Granda Orive JI, Martínez Albiach JM, Gutiérrez Jiménez T, Flórez Martín S, Solano Reina S, Jiménez Ruiz CA. Terapia sustitutiva con nicotina a altas dosis. Prev Tab 2002;4:136-41.
81. Barrueco M. Algunos aspectos de la terapia sustitutiva con nicotina (TSN) que podrían presentar dificultades para el clínico a partir de la información contenida en las fichas técnicas. Arch Bronconeumol 2001;37:219-20.
82. Jiménez Ruiz CA, Kunze M, Fagerström KO. Nicotine replacement: a new approach to reducing tobacco-related harm. Eur Resp J 1998;11:473-79.
83. Bolliger CT, Zellweger JP, Danielsson T, Biljon X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhaler: double blind, randomised clinical trial of efficacy and safety. BMJ 2000;321:329-33.
84. Jiménez Ruiz CA, Solano Reina S, Alonso Viteri S, Barrueco Ferrero M, Torrecilla García M, Hernández Mezquita M. Harm reduction. A treatment approach for resistant smokers with tobacco related symptoms. Respiration 2002;69:452-5.
85. Haustein KO, Krause J, Haustein H. How soon can biomarkers of hemorheology and cardiovascular harm detect smoking cessation or reduction. Paris: 3th European Conference of the Society for Research on Nicotine and Tobacco, 2001.
86. Jiménez Ruiz CA, Fagerström KO. Reducción del consumo de tabaco ¿una estrategia para dejar de fumar? Arch Bronconeumol Bronconcumol 1999;35:229-32.